Tyrosine Kinase Inhibitor

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

Remibrutinib reduced the need for rescue medication and improved symptoms among patients with chronic spontaneous urticaria, according to a study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress.

CHICAGO — Cabozantinib plus atezolizumab showed encouraging clinical activity in patients with inoperable locally advanced or metastatic urothelial carcinoma, according to data from the COSMIC-021 study.

CHICAGO — Asciminib continued to confer superior efficacy and better safety and tolerability than bosutinib among patients with chronic-phase chronic myeloid leukemia, according to study results presented during ASCO Annual Meeting.

BOSTON – In this video interview, Christy S. Harris, PharmD, BCOP, FHOPA, talked about poster sessions presented at Hematology/Oncology Pharmacy Association Annual Meeting.

BOSTON – Christy S. Harris, PharmD, BCOP, FHOPA, discussed a presentation on the role of immunotherapy in upper gastrointestinal cancer and how it’s “trying to move the needle forward” in care.

In a recent American Heart Association scientific statement, a committee provided an overview of drug-to-drug interactions between cancer drugs and commonly used CV medications.

As new therapeutic options for mantle cell lymphoma emerge, physicians are learning where they best fit into the treatment armamentarium.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses challenges in treating EGFR-mutated lung cancer.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses how diagnosis or biomarker testing of EGFR-mutated lung cancer has evolved.